A Phase 2 interventional study of imatinib mesylate in Hypereosinophilic Syndrome, sponsored by Novartis Pharmaceuticals. Terminated at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-05-01.
Sponsored by Novartis Pharmaceuticals · Phase 2, Interventional, and Treatment
The objectives of the study are:
76 studies on the registry are indexed under Hypereosinophilic Syndrome; 9 are open to participants now.
This study's enrollment of 24 is below the median of 48 across 65 interventional studies indexed under Hypereosinophilic Syndrome.
Browse Hypereosinophilic Syndrome studies →Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.
Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Idiopathic hypereosinophilic syndromes are included provided they belong to one of the following categories:
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply.
Drug: imatinib mesylate
Also known as: Gleevec/Glivec
Rate of complete and partial response and relapse
Bone Marrow Analysis
Peripheral blood detection of Fip1L1-PDGFRA tyrosine kinase
Disease-Related Symptoms and Signs
Organ Involvement
This study is terminated, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Pharmaceuticals